UNSPSC 51461502: Ipecacuanha extract

This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62I3C8233L, which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 846063 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Gentianales, Family Rubiaceae, Genus Carapichea, commonly known as IPECACUANHA.

European Medicines Agency schedules cinnamomum in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Indices SUB46920, SUB46936, SUB46937, SUB46938, SUB46939, SUB46940, and SUB46941.

UNSPSC 51461502 Ipecacuanha extract is a Commodity code under which state and local governments procure generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body identified in recent activity. State and local health agencies, correctional facilities, and other government healthcare providers purchase through these contracts to stock pharmaceutical inventories. Vendors supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and must maintain current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), and demonstrate pricing flexibility through fixed price, net price formats (NF30, NF60, NF90), or WAC-minus structures. All products require FDA approval, expiration dates of at least one year from manufacture, and a minimum six-month shelf life. Vendors must carry comprehensive insurance including workers' compensation, commercial general liability of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million, and must maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place.

MMCAP's RFP for Generic Multi Source Pharmaceuticals and OTC Products, posted January 20, 2026, represents the primary recent opportunity under this code, with proposals due March 26, 2026. The solicitation covers Minnesota and participating states including Oregon and spans state and local government facilities across those jurisdictions. Evaluation weights price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing (10 percent), administrative fee format compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Awarded contracts are effective July 1, 2026, for a two-year term with optional extensions at MMCAP's discretion; incumbent responders' amendments align with existing agreement expiration dates through June 30, 2028. The RFP does not identify specific set-aside designations or restrictions by business classification.